-+ 0.00%
-+ 0.00%
-+ 0.00%

MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.

Zhitongcaijing·11/20/2026 11:49:13
Listen to the news
MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.